Determination of soluble CD21 as a parameter of B cell activation.
In this study we established a novel solid-phase immunoassay for CD21 using the time-resolved fluorescence of lanthanide chelates. The capture assay was able to detect concentrations of as low as 100 pg of CD21 antigen per millilitre of sample and was used for quantitative determination of CD21 in lysates of different cell lines as well as in patient serum specimens. CD21 was measured in lysates of tonsils and cell lines of B, T cell and myelomonocyte lineage, and appeared to consist of monomeric antigen under the detergent conditions used. Elevated levels of soluble CD21 were observed in serum of patients with Epstein-Barr virus (EBV) infection, a disease known to be associated with polyclonal B cell activation, and in infection with the lymphotropic rubella virus. Significantly increased levels were also found in malignancies which are associated with EBV. In patients with nasopharyngeal carcinoma (NPC), a correlation with the titre of EBV-specific IgA was observed, thus supporting a possible role of soluble CD21 as a marker for disease activity in certain malignancies. Our data suggest that measurement of soluble CD21 could serve as a marker for activation of the immune system and diseases involving the B cell lymphoid system. Possible mechanisms and functions of soluble CD21 are discussed.
Huemer
H P
HP
Institute for Hygiene, University of Innsbruck, Austria.
Larcher
C
C
Prodinger
W M
WM
Petzer
A L
AL
Mitterer
M
M
Falser
N
N
D001402:B-Lymphocytes / Q000276:immunology*; D002460:Cell Line; D006801:Humans; D007244:Infectious Mononucleosis / Q000276:immunology; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology; D017464:Receptors, Complement 3d / Q000032:analysis*; D012409:Rubella / Q000276:immunology
D017464:Receptors, Complement 3d